ArticleInvestigational new drugs2023

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.

James Chih-Hsin Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.